Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat for Recurrent or Refractory Hodgkin's Lymphoma
NCT00132028Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2005
- Primary completion
- May 2009
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in Hodgkin lymphoma (HL), sponsored by National Cancer Institute. Primary endpoint: Response Probability (Complete and Partial Response). Started Sep 2005; status: completed.
02
Drugs
vorinostat
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00132028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132028.